Financial Health Snapshot
What do Johnson & Johnson’s latest financial health metrics show?
Strong. The strongest factor is profitability, with a 2183% Q1 2026 net margin and $270 adjusted EPS; the main concern is liquidity, plus legal overhang.
For Q1 2026, this view blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. Johnson & Johnson also matters for readers comparing investor behavior, including Exploring Johnson & Johnson (JNJ) Investor Profile: Who's Buying and Why?.
Revenue of $2410B in Q1 2026 and $9420B in full-year 2025, plus $1079 adjusted EPS for 2025, point to earnings conversion that still supports the case; the first metric to dig into is liquidity, especially the 1.03 current ratio and 0.77 quick ratio.
Revenue and Earnings Quality
Does Johnson & Johnson turn revenue growth into durable earnings?
Mixed. Johnson & Johnson showed strong earnings conversion in Q1 2026, with Operating Income of $640B, Net Income of $524B, and Adjusted EPS of $2.70, but the 1,040 basis point patent-expiration hit from STELARA and IMBRUVICA competition is the clearest divergence.
Revenue growth matters most when it turns into durable profit. Investors compare sales with operating income, net income, and EPS across compatible periods to see whether healthcare demand, mix, pricing, and portfolio changes are strengthening earnings quality or just lifting the top line temporarily.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $2410B in Q1 2026, with reported sales growth of 990% | $9420B in full-year 2025 | Unclear mix of organic growth and portfolio effects | Recurring healthcare demand supports repeatability, but the period mix is not directly comparable |
| Operating Income | $640B in Q1 2026 | Not provided | Faster earnings conversion is suggested, but the prior comparable value is unavailable | Higher operating income supports operating leverage |
| Net Income | $524B in Q1 2026 | Not provided | Final earnings were pressured by patent expirations and competition | Net income confirms profitability, but quality is not cleanly insulated from product-cycle pressure |
| Diluted EPS | $2.14 in Q1 2026 | $1.103 full-year 2025 diluted per-share net income | Per-share growth was supported, but the periods are not comparable and share-count effects are not provided | Shareholders saw stronger per-share earnings, though the comparison is only directional |
How durable is Johnson & Johnson’s revenue?
The strongest durability signal is recurring healthcare demand across Innovative Medicine and MedTech. The biggest visibility limitation is concentration in patent-sensitive products, especially STELARA and IMBRUVICA, which can distort near-term sales quality.
- Demand Quality: Recurring demand in oncology, immunology, neuroscience, cardiovascular, surgery, and vision supports visibility.
- Pricing and Volume: The price-volume split is not provided; patent losses and competition suggest the mix is not fully stable.
- Diversification: The planned DePuy Synthes Orthopaedics separation, about 3000% of the MedTech portfolio, is a portfolio-quality change, not completed performance.
That mix points investors toward profitability and cash conversion. Exploring Johnson & Johnson (JNJ) Investor Profile: Who's Buying and Why?
Margins and cash flow
Are Johnson & Johnson’s profits supported by cash flow?
Johnson & Johnson’s latest reported net margin is 2183%, but cash flow does not fully confirm that earnings strength yet. Profit growth looks much better than operating cash flow and free cash flow growth in the latest FMP period, so investors should check cash conversion carefully.
Johnson & Johnson reported $2406B of revenue, $1720B of gross profit, $640B of operating income, $599B of income before tax, $75500M of income tax expense, and $524B of net income for 2026-03-29. Gross margin and operating margin are not verified here, so the clearest read is that net income looks strong while cash generation still needs validation. R&D of $353B and selling, general and administrative expenses of $603B show ongoing reinvestment and a sizable cost structure. For a broader investor view, see Exploring Johnson & Johnson (JNJ) Investor Profile: Who's Buying and Why?
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Unavailable; not verified from supplied inputs. | Unavailable; no compatible prior margin supplied. | Gross profit and revenue are supplied, but the prompt says not to calculate the margin from those inputs. | Product economics cannot be confirmed from the provided data alone. |
| Operating Margin | Unavailable; not verified from supplied inputs. | Unavailable; no compatible prior margin supplied. | Operating income is supplied, but the prompt says not to calculate the margin from those inputs. | Scale and operating efficiency cannot be measured precisely here. |
| Net Margin | 2183% for Q1 2026. | Unavailable; no compatible prior margin supplied. | Net income of $524B on 2026-03-29 supports the reported margin. | Final profitability looks very strong, but the scale should be checked against cash conversion. |
| Operating Cash Flow | Growth of -6560% for 2026-03-29. | Unavailable; no compatible prior value supplied. | Working-capital effects and other cash items appear to have weakened cash generation. | Accounting earnings are not yet clearly translating into operating cash. |
| Free Cash Flow | Growth of -7323% for 2026-03-29. | Unavailable; no compatible prior value supplied. | Growth capital expenditure of 4290% points to a heavier investment burden. | Less cash remains after investment, which limits flexibility for financing and reinvestment. |
What most affects Johnson & Johnson’s cash conversion?
The strongest verified pressure is the sharp weakness in operating cash flow and free cash flow growth, alongside 4290% growth in capital expenditure. That looks more temporary than structural from the supplied data, but the cash bridge is still unclear.
- Main Driver: Cash conversion appears driven by heavier investment and weak working-capital flow, which looks temporary based on the limited data.
- Evidence Gap: The supplied data does not break out specific working-capital changes or non-cash items.
- Metric to Monitor: Operating cash flow, free cash flow, and capital expenditure.
Balance Sheet Strength
Is Johnson & Johnson’s balance sheet strong enough to support its obligations and investment needs?
Strong. Johnson & Johnson’s low leverage and AAA credit profile give it solid protection, but the main concern is a narrower short-term liquidity cushion because the Current Ratio of 103 and Quick Ratio of 077 are not especially roomy.
Cash alone does not tell the full story. Johnson & Johnson’s balance sheet needs to be judged by working capital, asset quality, debt service, solvency, liquidity, and refinancing together. The company’s mission, vision, and core values are also useful context for long-term discipline, and can be reviewed in Mission Statement, Vision, & Core Values (2026) of Johnson & Johnson (JNJ).
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Current Ratio of 103 and Quick Ratio of 077 for June 2026. | Mixed | Near-term obligations look manageable, but the liquidity cushion is not large enough to ignore working-capital pressure. |
| Total and Net Debt | Minus Cash And Cash Equivalents of $2169B and Add Total Debt of $1746B on 2026-03-29. | Strong | Leverage appears restrained, which supports flexibility for investment and reduces balance-sheet strain. |
| Debt Service and Refinancing | Interest Expense of $4300M and Net Interest Income of -$4300M for 2026-03-29; AAA rating support is consistent with strong credit access. | Strong | Low leverage improves refinancing flexibility and helps the company absorb funding pressure. |
| Asset Quality | Debt has fallen versus 2025-12-28, when Minus Cash And Cash Equivalents was $1971B and Add Total Debt was $4793B; FMP Debt Growth of -6357% for 2026-03-29. | Strong | Lower debt burden reduces impairment and capital-intensity stress, though investors should still watch asset mix and cash conversion. |
| Liabilities and Equity | Latest verified total liabilities and shareholders' equity were not supplied in the prompt. | Mixed | Without the full liability and equity totals, solvency can be judged only partially from the supplied debt and liquidity data. |
Which balance-sheet risk matters most for Johnson & Johnson?
The main risk is liquidity, not solvency. The Current Ratio of 103 and Quick Ratio of 077 suggest Johnson & Johnson can meet obligations, but it has less short-term cushion than its debt profile alone implies.
- Current Exposure: Current Ratio of 103 and Quick Ratio of 077 point to a modest near-term liquidity buffer.
- Protection: AAA rating and low leverage support refinancing access and financial flexibility.
- Warning Signal: Watch whether liquidity ratios weaken further or debt begins to rise again after the recent reduction.
Capital Efficiency
Are Johnson & Johnson’s returns strong enough to fund growth?
Strong. The verified 3260% ROE for Q1 2026 points to very high equity returns, but that figure is distorted by leverage and equity structure, not just operating strength. Internal cash appears likely to support reinvestment needs, but the verdict should still be tied to cash generation and balance-sheet flexibility.
Return quality should be read alongside leverage, asset intensity, capital expenditure, working capital needs, and any external funding. For Johnson & Johnson, the capital story is also shaped by the company profile in Johnson & Johnson (JNJ): History, Ownership, Mission, How It Works & Makes Money, where cash flow strength matters as much as accounting returns.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data. | Cannot test ROIC directly without verified invested capital and operating return data. | Investors should avoid treating the equity return as a full measure of operating value creation. |
| ROE and ROA | 3260% ROE for Q1 2026; Net Income of $524B; EPS Diluted of $214; Debt-to-Equity Ratio of 046. | ROE is very high, but leverage can inflate it; ROA is unavailable, so asset efficiency cannot be verified. | Shareholder returns look strong on paper, but leverage alone does not define the health verdict. |
| Maintenance and Growth Investment | $5500B over four years for domestic manufacturing, R&D, and technology; $200B biologics facility in Wilson, North Carolina; $200B biopharmaceutical facility in Holly Springs; hiring for advanced manufacturing roles at a $200B manufacturing campus; completed $1460B acquisition of Intra-Cellular Therapies; completed acquisitions of Halda Therapeutics and Atraverse Medical; definitive agreement to acquire Firefly Bio, Inc. | The spending mix clearly shows both expansion and capability-building, but the maintenance share is not separately disclosed. | Capital is being pushed into plants, technology, and acquisitions, so reinvestment demands are material. |
| Internal Funding Capacity | Quarterly dividend increased 310% to $134 per share; 64 consecutive years of dividend increases. | Dividend growth signals confidence, but internal funding cannot be confirmed without operating cash flow and free cash flow data. | The company appears to have capital allocation flexibility, yet full internal funding cannot be claimed from the supplied facts alone. |
Are Johnson & Johnson’s returns on capital sustainable?
Probably, because the strongest durability signal is the combination of very high reported ROE and ongoing reinvestment into manufacturing, R&D, and acquisitions. The main weak point would be a cash flow shortfall or rising funding needs that force more external capital.
- Operating Source: High reported ROE, supported by net income and disciplined capital allocation.
- Funding Requirement: The largest verified need is the $5500B four-year investment program and related facility buildout.
- Durability Test: Returns weaken if cash generation fails to keep pace with expansion, acquisitions, and dividend growth.
Legal pressure
How resilient is Johnson & Johnson’s financial health, and which warning signs matter most?
Strong. The main buffer is Johnson & Johnson’s low leverage and diversified cash generation across Innovative Medicine and MedTech. The most important verified warning sign is talc litigation, including the failed third bankruptcy attempt and 68,029 pending federal MDL lawsuits.
Johnson & Johnson still has room to protect liquidity, debt service, and core investment because it generates cash from two large businesses and can fund operations internally. That said, legal costs, patent erosion, and policy pressure can still squeeze free cash flow, so investors should watch the company’s ability to keep funding research, launches, and the Johnson & Johnson (JNJ): History, Ownership, Mission, How It Works & Makes Money platform without strain.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Talc litigation can absorb cash through verdicts, settlements, and defense costs, while patent loss and competition can reduce operating leverage, earnings, and debt capacity. | Diversified cash flow, profitability, and some legal offsets, including dismissal of some non-ovarian gynecologic cancer claims unless supported by new expert evidence and overturning of $95000M in punitive damages, while compensatory awards remained. | Rising legal accruals, worsening cash flow, or continued sales declines from STELARA and IMBRUVICA pressure. |
| Working-Capital or Investment Pressure | Higher litigation spending, tariff exposure, or supply-chain disruption can pull cash away from R&D, manufacturing, and expansion. | Internal funding capacity, a broad portfolio, and governance through the Enterprise Governance Council help preserve capital allocation discipline. | Weaker operating-cash-flow conversion, rising investment needs, or slower pipeline replacement. |
| Interest or Refinancing Pressure | Higher rates or refinancing needs would matter less than for highly levered peers, but they could still reduce flexibility if cash outflows rise. | Low leverage and access to diversified cash generation support financing flexibility. | Any increase in debt burden, tighter liquidity, or reduced free cash flow would show rising pressure. |
Which financial warning signs should investors monitor at Johnson & Johnson?
The top signals are talc litigation cash outflows, then patent-driven sales erosion, then policy or tariff pressure. The first is confirmed deterioration; the other two are future risks unless they show up in revenue, margin, or cash-flow trends.
Talc litigation cash burn
The failed third bankruptcy attempt, 68,029 pending federal MDL lawsuits, and ongoing verdict exposure can keep draining cash. The offset is case-specific legal wins, but the next metric is legal accruals and settlement activity.
Patent loss and competitive erosion
A 1,040 basis point negative impact from STELARA patent expirations and IMBRUVICA competition shows how quickly exclusivity loss can hit sales. The key mitigation is pipeline replacement, so watch segment revenue trends and new-launch uptake.
Tariffs and price controls
Potential tariffs and international price controls could raise costs or cap pricing power, even if the America-first reshoring strategy helps. The next metric is margin stability across markets and any sign of supply-chain cost inflation.
Financial Health Scorecard
How should investors score Johnson & Johnson’s financial health?
Overall, Johnson & Johnson scores Strong. Revenue growth and earnings quality are the best parts, while resilience is the weakest. The most important condition for the investment case is whether legal and patent pressure stays contained enough to protect capital and cash flexibility.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | Q1 2026 reported sales growth of 990%, Revenue of $2410B, full-year 2025 reported sales of $9420B, and Q1 2026 Adjusted EPS of $270 point to durable earnings conversion. |
| Profitability and Cash | Mixed | Net Margin of 2183% is strong, but FMP Operating Cash Flow Growth of -6560% and Free Cash Flow Growth of -7323% for 2026-03-29 need follow-up. |
| Balance Sheet and Liquidity | Strong | Debt-to-Equity Ratio of 046, Current Ratio of 103, and Quick Ratio of 077 suggest adequate liquidity and manageable leverage. |
| Capital Efficiency | Strong | ROE of 3260% supports efficient use of equity and suggests reinvestment can be funded without heavy dependence on outside capital. |
| Financial Resilience | Mixed | Talc litigation, patent expiration pressure, and policy risk can redirect capital and weaken flexibility even when core operations remain strong. |
- What Supports the Thesis: Strong sales, earnings, liquidity, and ROE give Johnson & Johnson solid capacity to fund operations and absorb shocks.
- What Challenges the Thesis: Talc-related litigation and patent pressure could consume cash and distract management from growth priorities.
- What to Monitor: Quick Ratio of 077, Free Cash Flow Growth of -7323%, and pending talc-related lawsuits of 68,029.
For background on the business model and history, see Johnson & Johnson (JNJ): History, Ownership, Mission, How It Works & Makes Money, then use those fundamentals to test forecasts, scenarios, and valuation assumptions.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Why is JNJ’s quick ratio below one?
JNJ’s Quick Ratio of 077 means quick assets do not fully cover current liabilities under that measure It does not prove distress because leverage is low, but it shows liquidity is adequate rather than abundant and deserves monitoring
How does talc litigation affect financial flexibility?
Talc litigation can affect flexibility by creating uncertain defense costs, verdict exposure, and possible settlement funding needs The risk remains material because pending talc-related lawsuits in the federal MDL reached 68,029, even though some rulings have reduced parts of the exposure
Is JNJ’s high ROE leverage-driven or profit-driven?
The supplied data show ROE of 3260% and Debt-to-Equity Ratio of 046 That combination suggests strong profitability is important to the return profile, while leverage appears conservative ROIC and ROA should not be inferred without verified figures
Can JNJ fund acquisitions and dividends internally?
JNJ has strong earnings, low leverage, and balance-sheet flexibility, which support acquisitions and dividends Investors should still test internal funding through operating cash flow, capital spending, and free cash flow conversion, especially after FMP Free Cash Flow Growth of -7323%
What could pressure JNJ’s margins next?
Margin pressure could come from STELARA patent expirations, IMBRUVICA competition, tariffs, international price controls, litigation costs, acquisition integration, and elevated reinvestment The key is whether new products, pipeline approvals, MedTech restructuring, and cost discipline offset these pressures